ST. LOUIS (March 26, 2013) – RiverVest Venture Partners’ Principal Niall O’Donnell, Ph.D., has been invited to serve on the Experts Panel at Stevenage Bioscience Catalyst, the U.K.’s first open innovation bioscience campus focused on driving early-stage biotech, pharma and medtech developments.
O’Donnell joins a panel of commercial, financial and technical experts advising Bioscience Catalyst and its tenants on all aspects of business development. Funded by partners including GlaxoSmithKline and the Wellcome Trust and located just outside of London, Stevenage Bioscience Catalyst’s goal is to stimulate the growth of the U.K. life sciences sector.
“I’m looking forward to this opportunity to advise the bioincubator and its promising entrepreneurs,” says O’Donnell. “At the same time, we at RiverVest will get an early look at some potential opportunities, which we think will enhance our deal flow.”
After joining RiverVest in 2006 as a Kauffman Fellow, O’Donnell became a principal in 2010. He focuses on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies.
O’Donnell earned his Ph.D. in Biochemistry from the University of Dundee, Scotland, and M.A. in Biochemistry from Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego.
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the U.K.’s first open innovation biomedical campus where companies, from start-ups to more mature firms, can benefit from proximity to the expertise and capabilities associated with a large pharmaceutical company. The joint involvement of the funding partners is designed to provide pharma and biotech companies with the opportunity to gain additional insights into a spectrum of translational research and development activities and opportunities.
By fostering a distinct culture of open innovation, Stevenage Bioscience Catalyst is creating an environment that will accelerate the pace of discovery towards product development and place the U.K. bioscience sector at the forefront of worldwide biomedical innovation, delivering cutting-edge healthcare solutions. For more information, please visit www.stevenagecatalyst.com.
About RiverVest Venture Partners®
RiverVest Venture Partners is a venture capital firm focused on identifying and shaping early-stage life science companies throughout the U.S. to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.
Established in 2000, RiverVest has funded 29 innovative life science companies and currently has assets under management of $208 million. For more information, please visit https://www.rivervest.com.